(The 9th China International Import Expo) The medical innovation incubation area of the 9th China International Import Expo opened and about 30 medical innovation achievements were unveiled.

China News Service, Shanghai, November 5 (Reporter Chen Jing) The 9th China International Import Expo (referred to as the "CIIE") opened in Shanghai on the 5th. The medical innovation incubation zone will welcome guests on the same day. About 30 medical innovations from the United States, Australia, Europe and other countries and regions were unveiled.

This year, there are a lot of "hard core" first-time products in the zone, such as Hong Kong's Roonao Technology, which has independently developed a new generation of ultra-fine flexible multi-modal implantable neural electrodes and brain-computer interface systems. The electrodes adopt ultra-fine filament-like flexible structures, which can better comply with the natural movement of brain tissue and reduce implant damage and inflammatory reactions. Dianqi Medical showcased its domestically developed venTOM-100 thoracic impedance tomography instrument, a non-invasive and radiation-free bedside lung function monitoring device that can dynamically display lung ventilation distribution in real time and promote ventilation management from "based on experience" to visualization and quantification.

Plinio Sergio Targa, CEO of an innovative company in Sao Paulo, Brazil, appeared in the special area with neuromonitoring products. "China's medical technology ecosystem is very complete. In the medical innovation incubation area, we can establish connections with all parties in the market and observe the real picture of China's innovative technology development at close range."

Boris Pasche is the founder of an innovative company based in the United States. He brought new technologies for the treatment of liver cancer. "China is very advanced in technology, and the level of clinical trials has improved significantly in the past 10 years. China is the perfect market to expand new technologies and conduct clinical trials."

Boston Scientific's Nalu neuromodulation system was named a representative "hard technology" exhibit at this year's CIIE. This is the eighth consecutive year that Boston Scientific has participated in the CIIE for the first time in the form of a "double booth" with the main booth of the medical device pavilion and the innovation incubation area. The main booth focuses on presenting global breakthrough minimally invasive technologies and local innovations; the special area focuses on the next generation of medical technology, showing how early-stage technologies can move toward clinical practice step by step through capital incubation and industry empowerment.

China's huge clinical needs, mature R&D capabilities and complete industrial system are giving birth to new innovation opportunities. Boston Scientific said that in the past 30 years, the company has continued to expand its presence in China and explore new technologies and solutions with Chinese medical institutions, scientific research teams and local innovative companies.